SCHEMBL209163

SCHEMBL209163

CCCCCC(=O)ON1C(=O)C=CC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.44
PTGS1 P23219 3/20 0.43
PTGS2 P35354 3/20 0.43
MGLL Q99685 2/20 0.43
FAAH O00519 1/20 0.43
LMNA P02545 2/20 0.42
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PAM P19021 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
BLM P54132 1/20 0.41
WRN Q14191 1/20 0.41
HIF1A Q16665 1/20 0.41
POLM Q9NP87 1/20 0.40
POLK Q9UBT6 1/20 0.40
POLL Q9UGP5 1/20 0.40
POLH Q9Y253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19067107 0.98 DGKA (0.47) DGKAPTGS1PTGS2MGLLFAAH
SCHEMBL4812972 0.98 DGKA (0.47) DGKAPTGS1PTGS2MGLLFAAH
SCHEMBL18960980 0.98 DGKA (0.47) DGKAPTGS1PTGS2MGLLFAAH
SCHEMBL2223792 0.98 DGKA (0.47) DGKAPTGS1PTGS2MGLLFAAH
SCHEMBL13356960 0.89 PTGS1 (0.44) DGKAPTGS1PTGS2MGLLFAAH
SCHEMBL714989 0.87 ALDH1A1 (0.44) PTGS1PTGS2MGLLFAAHLMNA
SCHEMBL28390950 0.87 ALDH1A1 (0.38) PTGS1PTGS2MGLLFAAHLMNA
SCHEMBL31121828 0.84 PTGS1 (0.53) PTGS1PTGS2LMNAMAPTTSHR
SCHEMBL2581743 0.82 ALDH1A1 (0.41) PTGS1PTGS2MGLLFAAHLMNA
SCHEMBL19704299 0.82 EPHX1 (0.46) LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116003306-B Synthesis method of linker compound of maleimidocaprooic acid-PEGn analogue 成都普康唯新生物科技有限公司 2024-09-10 CN claimed
CN-117447654-A Modified ethylene propylene diene monomer and preparation method thereof 合肥中科科乐新材料有限责任公司 2024-01-26 CN claimed
CN-113717255-B Polymyxin B and colistin hapten, artificial antigen, and preparation methods and applications thereof 中国农业大学 2023-04-28 CN claimed
CN-116003306-A Synthesis method of linker compound of maleimidocaprooic acid-PEGn analogue 成都普康唯新生物科技有限公司 2023-04-25 CN claimed
WO-2022198925-A1 NANO-MAGNETIC BEAD COATING, AND PREPARATION METHOD THEREFOR, DETECTION REAGENT THEREOF AND DETECTION KIT THEREOF 深圳市亚辉龙生物科技股份有限公司 2022-09-29 WO claimed
CN-113350576-A Fast-slow crosslinking complementary double-network self-healing injectable hydrogel and preparation method thereof 上海大学 2021-09-07 CN claimed
CN-103897053-A Chemically modified thymulin alpha 1 and synthetic method thereof SHENZHEN INST OF ADV TECH CAS 2014-07-02 CN claimed
CN-103897031-A Chemically modified thymopentin and synthetic method thereof SHENZHEN INST OF ADV TECH CAS 2014-07-02 CN claimed
US-12606723-B2 Thermosetting resin composition, semiconductor device and electrical/electronic component KYOCERA CORPORATION (JP) 2026-04-21 US disclosed
EP-4642487-A1 ANTIBODY-DRUG CONJUGATES TARGETING UPARAP COMPRISING EXATECAN DERIVATIVES Adcendo ApS (DK) 2025-11-05 EP disclosed
US-20250213713-A1 Antibody-Drug Conjugates Targeting uPARAP Comprising Exatecan Derivatives ADCENDO APS (DK) 2025-07-03 US disclosed
CN-120153462-A Adhesive film, temporary fixing material, cured product, laminate, and method for producing electronic component 积水化学工业株式会社 2025-06-13 CN disclosed
CN-113574083-B Adhesive composition, adhesive tape, and method for treating electronic component 积水化学工业株式会社 2025-06-10 CN disclosed
CN-120078904-A Conjugates of cytotoxic drugs and prodrug forms of the conjugates 辛迪维亚公司 2025-06-03 CN disclosed
EP-0647849-A2 Detecting the presence of analytes in a sample IGEN, INC. (US) 1995-04-12 EP disclosed
US-5393527-A Siloxane or fluorosiloxane liquid hydrophobic core, an amphiphilic compound phospholipid forming monolayer on surface of particle such that ligand is capable of binding to a receptor for the ligand BECTON, DICKINSON AND COMPANY (US) 1995-02-28 US disclosed
EP-0606613-A1 Stabilized microspheres and methods of preparation Becton, Dickinson and Company (US) 1994-07-20 EP disclosed
EP-0265519-A4 ELECTROCHEMILUMINESCENT ASSAYS. IGEN INC (US) 1990-05-14 EP disclosed
EP-0265519-A1 ELECTROCHEMILUMINESCENT ASSAYS. IGEN INC (US) 1988-05-04 EP disclosed
WO-1987006706-A1 ELECTROCHEMILUMINESCENT ASSAYS IGEN, INC. (US) 1987-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213713-A1 Antibody-Drug Conjugates Targeting uPARAP Comprising Exatecan Derivatives PLAUR, ENTPD8, ENTPD3 DGKA 2631/4885PTGS1 4401/4885PTGS2 3973/4885
US-12606723-B2 Thermosetting resin composition, semiconductor device and electrical/electronic component RPS3A, SEM1, DAP3 DGKA 3082/4885PTGS1 1071/4885PTGS2 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.